Hexarelin dosage: reported doses and schedule
A peptide that releases growth hormone; repeated use can weaken the response.
Also called: Examorelin, HEX, EP-23905, MF-6003.
Growth hormone secretagogues (ghrelin receptor) · Ghrelin receptor agonist and growth hormone secretagogue.
Typical reported dose: 50–200 mcg two or three times a day
- IV dose test: 0.5: 0.5 mcg/kg IV once; ascending single-dose tests. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- IV dose test: 1: 1 mcg/kg IV once; ascending single-dose tests. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- IV dose test: 2: 2 mcg/kg IV once; ascending single-dose tests. once per test day, into a vein. Studied in a trial. Studied in: Adults in the cited study. (source)
- Single SC challenge: 1.5: 1.5 mcg/kg SC once. once per acute test, under the skin. Studied in a trial. Studied in: Adults in the cited study. (source)
- Single SC challenge: 3: 3 mcg/kg SC once. once per acute test, under the skin. Studied in a trial. Studied in: Adults in the cited study. (source)
- Single nasal challenge: 20 mcg/kg intranasally once. once per acute test, nasal spray. Studied in a trial. Studied in: Adults in the cited study. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Hexarelin
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- MK-677 (ibutamoren): This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
- GHRP-2: A peptide that releases growth hormone and can increase hunger.
- GHRP-6: A peptide studied in growth hormone tests and an experimental stroke combination.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- GENOTROPIN® (somatropin) for injection, for subcutaneous use, FDA · 2025
- 注射用GHRP科研100, PMDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.